# DESCRIPTION

## FIELD OF THE INVENTION

- relate to bifunctional compounds for neurological diseases

## BACKGROUND OF THE INVENTION

- introduce Alzheimer's disease
- describe tau protein and its role in AD
- discuss current therapeutic strategies
- highlight need for new treatments

## SUMMARY OF THE INVENTION

- introduce PROTAC strategy
- describe bifunctional compounds
- define tau binding moiety
- define E3 ubiquitin ligase binding moiety
- describe linker
- provide formula I
- describe T-I formula
- define L, M, P, Q, X, R1-8, and R9
- describe R3
- describe A
- provide T-II formula
- describe X1-5, R13-15, and R14
- describe T-III and T-IV formulas
- define R20-24, G, Rx, and Ry
- describe E3 ubiquitin ligase binding moiety
- provide exemplary compounds
- describe radiolabeled compounds
- describe pharmaceutical compositions
- describe methods of treating neurological disorders
- describe methods of promoting tau degradation
- describe methods of detecting neurological disorders
- describe methods of diagnosing neurological disorders
- describe kits

## DEFINITIONS

### Chemical Definitions

- define chemical elements
- introduce functional groups
- discuss stereoisomers
- describe isomer isolation methods
- define bond notation
- discuss isotopically enriched atoms
- explain range of values
- define aliphatic and heteroaliphatic groups
- describe alkyl groups
- discuss haloalkyl groups
- provide examples of alkyl and haloalkyl groups
- define heteroalkyl
- specify heteroalkyl embodiments
- define alkenyl
- specify alkenyl embodiments
- define heteroalkenyl
- specify heteroalkenyl embodiments
- define alkynyl
- specify alkynyl embodiments
- define heteroalkynyl
- specify heteroalkynyl embodiments
- define carbocyclyl
- specify carbocyclyl embodiments
- define cycloalkyl
- specify cycloalkyl embodiments
- provide examples of cycloalkyl groups
- specify unsubstituted or substituted cycloalkyl
- define monocyclic carbocyclyl
- specify monocyclic carbocyclyl embodiments
- define saturated carbocyclyl
- specify saturated carbocyclyl embodiments
- provide examples of carbocyclyl groups
- specify unsubstituted or substituted carbocyclyl
- define fused carbocyclyl
- specify fused carbocyclyl embodiments
- provide examples of fused carbocyclyl groups
- specify unsubstituted or substituted fused carbocyclyl
- define polycyclic carbocyclyl
- specify polycyclic carbocyclyl embodiments
- provide examples of polycyclic carbocyclyl groups
- specify unsubstituted or substituted polycyclic carbocyclyl
- define heterocyclyl
- describe heterocyclyl groups
- exemplify heterocyclyl groups
- define aryl
- describe aryl groups
- exemplify aryl groups
- define heteroaryl
- describe heteroaryl groups
- exemplify heteroaryl groups
- define aralkyl
- define heteroaralkyl
- define unsaturated bond
- define unsaturated
- define saturated
- explain suffix "-ene"
- describe optional substitution
- exemplify substituents
- describe substituents on nitrogen
- describe substituents on carbon
- describe substituents on sulfur
- describe substituents on oxygen
- describe substituents on phosphorus
- describe substituents on boron
- describe alkyl substituents
- describe perhaloalkyl substituents
- describe alkenyl substituents
- describe alkynyl substituents
- describe heteroalkyl substituents
- describe heteroalkenyl substituents
- describe heteroalkynyl substituents
- describe carbocyclyl substituents
- describe heterocyclyl substituents
- define Raa
- define Rbb
- define Rcc
- define Rdd
- define Ree
- define Rff
- define Rgg
- define halo
- define hydroxyl
- define substituted hydroxyl
- define amino
- define substituted amino
- define monosubstituted amino
- define disubstituted amino
- define trisubstituted amino
- define sulfonyl
- define sulfinyl
- define acyl
- describe acyl substituents
- provide examples of acyl groups
- define carbonyl group
- define silyl group
- define oxo and thiooxo groups
- describe nitrogen atom substituents
- introduce nitrogen protecting groups
- list nitrogen protecting groups
- describe amide nitrogen protecting groups
- list amide nitrogen protecting groups
- describe carbamate nitrogen protecting groups
- list carbamate nitrogen protecting groups
- describe sulfonamide nitrogen protecting groups
- list sulfonamide nitrogen protecting groups
- provide reference for nitrogen protecting groups
- conclude chemical definitions
- define nitrogen protecting groups
- list examples of nitrogen protecting groups
- define oxygen protecting groups
- list examples of oxygen protecting groups
- define sulfur protecting groups
- list examples of sulfur protecting groups
- define counterion
- list examples of counterions
- define leaving group
- list examples of leaving groups
- explain use of phrase "at least one instance"
- define non-hydrogen group
- introduce chemical definitions
- describe nitrogen protecting groups
- describe oxygen protecting groups
- describe sulfur protecting groups
- describe counterions
- describe leaving groups
- provide general information on protecting groups
- reference external source for protecting groups
- describe scope of invention
- provide examples of substituents
- describe use of substituents
- conclude chemical definitions

### Other Definitions

- define salt
- describe pharmaceutically acceptable salt
- provide examples of pharmaceutically acceptable salts
- define solvate
- describe types of solvates
- define hydrate
- describe types of hydrates
- define tautomers
- describe tautomerization
- define isomers
- describe stereoisomers
- define diastereomers
- define enantiomers
- describe absolute configuration
- define polymorph
- describe differences between polymorphs
- define prodrugs
- describe types of prodrugs
- define composition and formulation
- define subject
- describe types of subjects
- define patient
- define biological sample
- describe types of biological samples
- define tissue
- describe types of tissues
- define administer
- describe modes of administration
- define treatment
- describe goals of treatment
- define condition, disease, and disorder
- define effective amount
- describe factors affecting effective amount
- define therapeutically effective amount
- describe benefits of therapeutically effective amount
- define prophylactically effective amount
- describe benefits of prophylactically effective amount
- define neurological disorder
- define tau protein
- define tauopathy

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

- introduce bifunctional compounds

### Compounds

- introduce compounds interacting with tau protein and E3 ubiquitin ligase
- describe therapeutic effect of compounds
- define compound of Formula I
- specify T as tau protein binding moiety
- specify E as E3 ubiquitin ligase binding moiety
- define L as linker
- describe Group T
- define T as tau protein binding moiety derived from prior art
- specify T of Formula T-I
- describe embodiments of Formula T-I
- specify embodiments of L, M, P, Q, X, R3, and R1-8
- define compounds
- specify R9
- specify R3
- specify R1, R2, and R4
- introduce formula T-I-a
- define L, M, X, R9, R3, A, R2, R7, R8, and n
- specify R3 in formula T-I-a
- introduce formula T-I-b
- specify R3 in formula T-I-b
- specify R3 in formula T-I-b
- specify R3 in formula T-I-b
- specify R3 in formula T-I-b
- specify R3 in formula T-I-b
- specify R3 in formula T-I-b
- specify R3 in formula T-I-b
- specify R3 in formula T-I-b
- define compounds
- specify formula T-II
- define R13, R14, and R15
- specify embodiments of Formula T-II
- specify formula T-II-a
- define R13, R14, and R15 for T-II-a
- specify embodiments of Formula T-II-a
- specify formula T-II-b
- define R14 for T-II-b
- specify embodiments of Formula T-II-b
- specify formulas T-III and T-IV
- define R20, R21, G, R22, R23, R24, Rx, Ry, n, t, and r
- specify formula T-III
- define R20, R21, G, R22, Rx, Ry, n, t, and r for T-III
- specify formula T-III-a
- define R20, G, R22, Rx, Ry, and n for T-III-a
- specify additional embodiments of T
- specify additional formulas for T
- define compounds
- specify R20
- specify G
- specify R22
- specify T
- specify R21
- specify R23
- specify R24
- specify Rx and Ry
- specify tau binding moiety
- specify selectivity
- introduce Group L
- specify L
- specify atoms in L
- specify carbon atoms in L
- specify alkylene in L
- specify heteroalkylene in L
- specify formulas for L
- specify q, u, p, and s in L
- define compounds
- specify L
- specify RA
- introduce E3 ubiquitin ligase
- describe Cereblon
- specify E
- describe E as modulator, binder, inhibitor, or ligand of Cereblon
- specify E as modulator, binder, inhibitor, or ligand of Cereblon variant or isoform
- describe E as comprising heteroaryl ring
- describe E as comprising fused bicyclic heteroaryl ring
- describe E as comprising phthalimido group
- specify E of Formula E-I
- specify Y in Formula E-I
- specify R1A, R3A, R3', R4A, and R5A in Formula E-I
- specify E of Formula E-II or E-III
- specify Y in Formula E-II or E-III
- specify XA and X1-X2 in Formula E-II or E-III
- specify R1A, R3A, R3', R4A, and R5A in Formula E-II or E-III
- describe E3 ubiquitin ligase complex
- describe Cereblon ubiquitination of target proteins
- describe regulation of fibroblast growth factor 8 and 10
- describe developmental processes regulated by FGF8
- incorporate references
- define compounds
- specify m and n values
- define E of formula E-II
- specify Y, XA, X1-X2, RB, R1A, R3A, R3', R4A, R5
- define certain embodiments of formula E-II
- specify Y, XA, X1-X2, RB, R1A, R3A, R3', R4A, R5
- define certain embodiments of formula E-II
- specify Y, XA, X1-X2, RB, R1A, R3A, R3', R4A, R5
- define E of formula E-II-a
- specify Y, XA, RB, R1A, R3A, R4A, R5
- define certain embodiments of formula E-II-a
- specify Y, XA, RB, R1A, R3A, R4A, R5
- define E of formula E-II-b
- specify Y, XA, RB, R3A, R4A, R5
- define certain embodiments of formula E-II-b
- specify Y, XA, RB, R3A, R4A, R5
- define E of formula E-II-c
- specify Y, RB, R4A, R5
- define certain embodiments of formula E-II-c
- specify Y, RB, R4A, R5
- define E of formula E-II-d, E-II-e, E-II-f, E-II-g
- define compounds
- specify R4A and R5A
- define E of Formula E-III
- specify Y in Formula E-III
- specify X1-X2 in Formula E-III
- specify RB in Formula E-III
- specify R1A in Formula E-III
- specify R3A in Formula E-III
- specify R3' in Formula E-III
- define E of Formula E-III-a
- define E of Formula E-III-b
- specify Y in Formula E-III-b
- define compounds
- specify Y
- specify X1-X2
- specify RB
- specify R3A
- specify R4A
- specify R5A
- specify k
- describe E-III-c
- describe E-III-d
- describe E-III-d-1
- describe E-III-d-2
- describe E-III-e
- describe E-III-e-1
- describe E-III-e-2
- describe VHL
- describe VHL structure
- describe E as VHL modulator
- describe E as peptide backbone structure
- describe E3 ligase binding moiety
- describe selectivity of E3 ligase binding moiety

### Further Embodiments of Formula I

- define compound of Formula I-a
- specify E3 ubiquitin ligase binding moiety
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- specify optional replacement of carbon in R2, R3, R7, and R8
- define L, M, X, R9, R3, A, R2, R7, R8, R12, n, and
- define formula I
- specify R9
- specify R3
- specify A
- specify R2, R7, R8
- specify n and q
- define formula I-a
- specify L, M, X, R9, R3, A, R2, R7, R8, n, q
- define formula I-b
- specify E, R3, A, n, q
- define formula I-b-1, I-b-2, I-b-3, I-b-4, I-b-5
- specify E, q
- define formula I-c
- define formula I-c
- specify X3, X4, X5, R14, R15, A, n, q
- specify R14, A, n, q
- specify R14, A, n, q
- specify R14, A, n, q
- specify R14, A, n, q
- define formula I-d
- specify R14, A, n, q
- specify R14, A, n, q
- specify R14, A, n, q
- specify R14, A, n, q
- specify R14, A, n, q
- define formula I-d-1
- specify E, q
- define formula I-e
- specify E, R20, G, R22
- specify R20
- specify R22
- define Rx and Ry
- define n and q
- define R20
- define G
- define R22
- define embodiment of Formula I-e
- define embodiment of Formula I-e
- define embodiment of Formula I-e
- define embodiment of Formula I-e
- define embodiment of Formula I-e
- define embodiment of Formula I-e
- define embodiment of Formula I-f
- define embodiment of Formula I-f
- define embodiment of Formula I-f
- define embodiment of Formula I-f
- define embodiment of Formula I-f
- define embodiment of Formula I-f
- define embodiment of Formula I-f
- define embodiment of Formula I-g
- define embodiment of Formula I-h
- define embodiment of Formula I-i
- define embodiment of Formula I-j
- define embodiment of Formula I-k
- define embodiment of Formula I-1
- define embodiment of Formula I-m
- define embodiment of Formula I-n
- define embodiment of Table 1
- define embodiment of Table 2
- define radionuclide
- define tau protein binding
- define E3 ubiquitin ligase binding
- define Cereblon binding

### Pharmaceutical Compositions, Kits, and Administration

- define pharmaceutical compositions
- describe compound of Formula I
- specify effective amount
- describe therapeutically effective amount
- describe prophylactically effective amount
- describe amount for treating neurological disorder
- describe amount for preventing neurological disorder
- describe amount for treating neurodegenerative disease
- describe amount for preventing neurodegenerative disease
- describe amount for treating tauopathy
- describe amount for preventing tauopathy
- describe amount for reducing disease risk
- specify subject
- describe animal subject
- describe human subject
- describe non-human animal subject
- describe mammal subject
- describe non-human mammal subject
- describe domesticated animal subject
- describe companion animal subject
- describe livestock animal subject
- describe zoo animal subject
- describe research animal subject
- describe genetically engineered animal subject
- describe transgenic animal subject
- describe fish or reptile subject
- describe effective amount for tau protein degradation
- describe pharmaceutical composition for treating neurological disorder
- describe pharmaceutical composition for treating neurodegenerative disease
- describe pharmaceutical composition for treating tauopathy
- describe administration with additional pharmaceutical agents
- describe solid pharmaceutical composition
- describe liquid pharmaceutical composition
- describe administration routes
- describe pharmaceutical composition preparation
- list antioxidants
- list chelating agents
- list antimicrobial preservatives
- list antifungal preservatives
- list alcohol preservatives
- list acidic preservatives
- list other preservatives
- list buffering agents
- list lubricating agents
- list natural oils
- list synthetic oils
- describe liquid dosage forms
- list inert diluents
- list adjuvants
- describe injectable preparations
- list vehicles and solvents
- describe sterilization methods
- describe solid dosage forms
- list excipients
- list fillers or extenders
- list binders
- list humectants
- list disintegrating agents
- list solution retarding agents
- list absorption accelerators
- list wetting agents
- list absorbents
- list lubricants
- describe coatings and shells
- describe micro-encapsulated form
- describe topical formulations
- describe kits
- describe kit contents and instructions

### Methods of Treatment

- motivate tau protein degradation
- describe tau protein aggregation
- introduce bifunctional compounds
- describe Cereblon binding
- provide methods for treating neurodegenerative diseases
- provide methods for treating tauopathies
- list specific tauopathies
- provide methods for promoting tau protein degradation
- describe administering compounds to subjects
- describe compounds of Formula I
- provide uses of compounds of Formula I
- describe manufacturing medicaments
- describe administering effective amounts
- describe therapeutically effective amounts
- describe prophylactically effective amounts
- describe treating animals
- describe treating humans
- describe treating domesticated animals
- describe treating companion animals
- describe treating livestock animals
- describe treating zoo animals
- describe administering additional pharmaceutical agents

### Diagnostic Methods

- motivate in vivo imaging of tau protein
- describe early diagnosis of neurological diseases
- introduce radiolabeled compounds of Formula I
- describe fluorescence imaging techniques
- describe nuclear imaging techniques
- describe PET imaging
- describe SPECT imaging
- provide methods for detecting neurological disorders
- provide methods for detecting tauopathies
- provide methods for detecting Alzheimer's disease
- describe contacting compounds with tissue
- describe administering compounds to subjects
- describe imaging tau protein in subjects
- describe diagnosing neurological disorders

## EXAMPLES

- provide examples of compounds and their preparation

### Preparation of Synthetic Intermediates

- prepare compound C
- prepare compound D
- prepare compound E
- prepare compound F
- prepare compound G
- prepare compound H
- prepare compound I
- prepare compound J
- describe purification methods

### N-(6-02-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide (1; QC-01-178))

- prepare compound 1
- characterize compound 1 by NMR

### (2S,4R)-1-[(2S)-3,3-Dimethyl-2-(3-{2-[2-(3-{5H-pyrido[4,3-b]indol-7-yl}propanamido)ethoxy]ethoxy}propanamido)butanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-earboxamide (8; FMF-05-129-1)

- prepare compound M
- prepare compound N
- prepare compound 8
- characterize compound 8 by NMR

### 2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy}-N-{2-[2-(2-{2-[(5-{5H-pyrido[4,3-b]indol-7-yl}pyridin-2-yl)oxy]acetamido}ethoxy)ethoxy]ethyl}acetamide (15; FMF-05-183-1)

- prepare compound R
- prepare compound S
- prepare compound U
- prepare compound V
- prepare compound 15
- characterize compound 15
- provide MS data for compound 15

### N-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)ethyl]-2-[(5-{5H-pyrido [4,3-b]indol-7-yl}pyridirt-2-yl)oxy]acetamide (19; FMF-05-167-1)

- prepare compound 19
- characterize compound 19
- provide MS data for compound 19
- prepare example compounds 16-18
- prepare compound AA
- prepare compound BB
- prepare compound 20

### Tau Degradation Assays

- introduce tau degradation assays
- describe experimental design
- introduce example compounds 1-12
- describe treatment of neurons with compounds
- describe protein extraction and quantification
- describe Western blot analysis
- present results of tau degradation assays
- evaluate effect of T807 on tau levels
- reevaluate example compounds 2-5
- describe effect on E3 ubiquitin ligases
- present results of Western blot analysis
- evaluate effect of compounds on CRBN, VHL, and CHIP
- describe tau accumulation in A152T and P301L neurons
- evaluate effect of compounds on CHIP levels
- describe evaluation of example compounds 2-5 in non-mutant control neurons
- present results of Western blot analysis
- evaluate dose-dependent effect of compounds on tau
- describe evaluation of compounds in rescue stress vulnerability assay
- present results of rescue stress vulnerability assay
- summarize findings of tau degradation assays

### In Vivo Assay

- introduce in vivo assay
- describe animal husbandry
- describe formulation and dosing of compound 3
- describe sample collection and processing
- describe bioanalytical method development
- present results of in vivo assay

## Equivalents And Scope

- define claim language
- interpret or relationships
- include variations and combinations
- disclose subgroup elements
- understand open-ended terms
- incorporate references by reference
- determine scope of invention

